SWOG Cancer Research Network
swog.orgTotal trials
336
Active
55
Phase 3
91
Total enrollment
180,820
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 115 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ruxolitinib | — | — | — | — | 2 | ||
| Momelotinib | — | — | — | — | — | 1 | |
| Ramucirumab | — | — | — | — | 9 | ||
| cyclophosphamide | — | — | — | 38 | |||
| dexamethasone | — | — | — | — | 21 | ||
| Pembrolizumab | — | — | — | — | 5 | ||
| docetaxel | — | — | 28 | ||||
| paclitaxel | — | — | — | — | 26 | ||
| prednisone | — | — | — | 24 | |||
| carboplatin | — | — | — | — | 22 | ||
| Lenalidomide | — | — | — | — | 6 | ||
| Ipilimumab | — | — | — | 4 | |||
| Nivolumab | — | — | — | 4 | |||
| doxorubicin hydrochloride | — | — | — | — | 23 | ||
| fluorouracil | — | — | — | — | 17 | ||
| bortezomib | — | — | — | — | 8 | ||
| Gemcitabine | — | — | — | — | 8 | ||
| Leucovorin | — | — | — | — | 5 | ||
| goserelin acetate | — | — | — | — | 5 | ||
| Irinotecan | — | — | — | — | 4 | ||
| Daratumumab and Hyaluronidase-fihj | — | — | — | — | — | 2 | |
| leuprolide acetate | — | — | — | — | — | 2 | |
| Chemotherapy | — | — | — | — | 3 | ||
| rituximab | — | — | — | — | 14 | ||
| melphalan | — | — | — | — | 9 | ||
| doxorubicin | — | — | — | — | 7 | ||
| vincristine | — | — | — | — | 5 | ||
| everolimus | — | — | — | 5 | |||
| trastuzumab | — | — | — | — | 5 | ||
| bicalutamide | — | — | — | — | 5 | ||
| Pemetrexed | — | — | — | — | 4 | ||
| tamoxifen citrate | — | — | — | — | — | 4 | |
| anastrozole | — | — | — | — | 4 | ||
| Nab-paclitaxel | — | — | — | — | — | 2 | |
| Pertuzumab | — | — | — | — | 2 | ||
| pegfilgrastim | — | — | — | — | 2 | ||
| flutamide | — | — | — | — | 2 | ||
| nilutamide | — | — | — | — | 2 | ||
| Lanreotide | — | — | — | — | — | 1 | |
| Irinotecan Sucrosofate | — | — | — | — | — | 1 |
75 more active programs hidden
Next readouts
- 2015-01
- 2019-12-19
- 2022-12-01
- 2024-07-01
- 2025-04-08
- 2025-11-26
- 2025-12-31
- 2026-05-31
- 2026-08-01
- 2026-08-01
Top conditions
- Breast Cancer41
- Lymphoma34
- Lung Cancer30
- Leukemia27
- Prostate Cancer16
- Colorectal Cancer14
- Multiple Myeloma13
- Stage IV Lung Cancer AJCC v813
Frequently asked questions about SWOG Cancer Research Network
- How many clinical trials does SWOG Cancer Research Network have on ClinicalTrials.gov?
- SWOG Cancer Research Network is listed as the lead sponsor on 336 clinical trials in ClinicalTrials.gov, 55 of which are currently active (recruiting, enrolling, or ongoing).
- How many of SWOG Cancer Research Network's trials are in Phase 3?
- 91 of SWOG Cancer Research Network's trials are in Phase 3, spread across 115 active drug programs.
- What therapeutic areas does SWOG Cancer Research Network focus on?
- SWOG Cancer Research Network's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Lymphoma, Lung Cancer, Leukemia, Prostate Cancer.
- When are SWOG Cancer Research Network's next clinical trial readouts?
- SWOG Cancer Research Network has 10 upcoming primary-completion readouts tracked here; the soonest is “S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer”, expected around 2015-01.